Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which ...

ICICI Securities recommended hold rating on Zydus Lifesciences with a target price of Rs 1000 in its research report dated.

Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 1050 in its research report ...

Zydus Lifesciences Ltd (BOM:532321) reports a robust 17% revenue increase and significant advancements in its innovation pipeline amidst market challenges.

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

US formulation sales for Zydus Life during the quarter stood at $285 million, which is a growth of 29% on a year-on-year ...

Ahead of the market opening on Friday, February 7, analysts from domestic brokerages have recommended several stocks for ...

The United States is the company's biggest market accounting for 47 per cent of total revenue, followed by India ...

Zydus Wellness’ revenue from operations stood at ₹450.8 crore in the December 2024 quarter, rising 12.7% on a YoY basis.

Earnings: Zydus Lifesciences reported a 30% YoY rise in Q3FY25 net profit to ₹1,023.5 crore, driven by strong US growth.

Zydus Lifesciences Q3 profit rises 30% to Rs 1,023 crore, driven by strong US and domestic market sales. Revenue also ...

Zydus Wellness Ltd (BOM:531335) reports robust sales growth and market leadership amid inflationary pressures and urban demand challenges.